Kissei Pharmaceutical has patented a method for treating endometriosis by administering a GnRH antagonist based on the patient’s AMH or E2 levels. The method aims to reduce endometriosis-associated pain in female patients. GlobalData’s report on Kissei Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kissei Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Kissei Pharmaceutical's grant share as of May 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of endometriosis-associated pain with gnrh antagonist
A recently granted patent (Publication Number: US11980621B2) discloses a method for reducing endometriosis-associated pain and treating endometriosis in female human patients. The method involves administering a compound represented by formula (II) to the patient. Additionally, the method aims to reduce the concentration of ß17-estradiol, follicle-stimulating hormone, and/or luteinizing hormone in patients with endometriosis by administering the compound.
Furthermore, the patent claims specify the administration of the compound in the form of the choline salt of formula (II), orally, and once daily. It also includes the provision of add-back therapy to the patient, which may consist of estrogen (such as ß17-estradiol) and progestin (like norethindrone acetate) in specific amounts. The patent also covers kits comprising the compound represented by formula (II), with the compound potentially being present in the form of the choline salt of formula (II) in the kit. These claims highlight a novel approach to managing endometriosis and associated symptoms, potentially offering new treatment options for patients in need.
To know more about GlobalData’s detailed insights on Kissei Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
